Proxy Votes Now

Home › Funds › Alger Health Sciences Fund

Alger Health Sciences Fund (AHSAX) proxy voting record 2025-2026

Fund family: ALGER FUNDS · Filed by ALGER FUNDS (CIK 3521) · SEC series S000009164

Share classes and tickers: AHSAX (C000024915), AHSCX (C000024917), AHSZX (C000156505)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 618 with, 17 against, 0 abstentions (not counted as with management). Shareholder proposals: 13 FOR, 3 AGAINST, 0 abstained, by the filing’s own vote-source field.

Where this fund voted differently from most ALGER FUNDS funds

Each ballot item this fund voted is set against the votes of the other ALGER FUNDS funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most ALGER FUNDS funds on all 107 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 76.9% of this fund’s 635 such votes could be given a sector; the other 147 (23.1%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care423153.5%
Real Estate3000.0%
Consumer Staples1715.9%
Technology1000.0%
Finance800.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections4050
Audit-related580
Say-on-Pay490
Corporate Governance4610
Compensation370
Capital Structure310
Other Social Issues64
Environment or Climate33
Extraordinary Transactions10
Other10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
McKesson CorporationJuly 30, 2025$5M140
Cardinal Health, Inc.November 5, 2025$4M140
Teva Pharmaceutical Industries LimitedMay 28, 2026$3M30
Veeva Systems Inc.June 17, 2026$3M100
Welltower Inc.May 21, 2026$3M110
Merck & Co., Inc.May 26, 2026$3M183
Johnson & JohnsonApril 23, 2026$3M151
Eli Lilly and CompanyMay 4, 2026$3M102

Notable votes against management

MeetingCompanyProposalFundMgmt
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalForAgainst
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalForAgainst
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalForAgainst
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalForAgainst
April 23, 2026HCA Healthcare, Inc.Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences. Shareholder proposalForAgainst
April 23, 2026HCA Healthcare, Inc.Stockholder proposal, if properly presented at the meeting, regarding stockholders' right to act by written consent. Shareholder proposalForAgainst
May 14, 2026CVS Health CorporationStockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposalForAgainst
May 12, 2026Centene CorporationSTOCKHOLDER PROPOSAL REGARDING AN INDEPENDENT BOARD CHAIRMAN. Shareholder proposalForAgainst

Search this fund’s votes by company

638 ballot items at 54 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Alger Health Sciences Fund (AHSAX) voted at 54 shareholder meetings of 54 companies, on 638 ballot items in all. Where management made a recommendation, the fund followed it on 97.3% of the items and voted against it 17 times. Its most frequent area of disagreement was corporate governance (10 of its votes against management). It voted on 16 shareholder proposals. It voted the same way as most ALGER FUNDS funds on every item where a comparison was possible.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.